EP1695661B1 - Nuclear magnetic resonance device - Google Patents
Nuclear magnetic resonance device Download PDFInfo
- Publication number
- EP1695661B1 EP1695661B1 EP03772935A EP03772935A EP1695661B1 EP 1695661 B1 EP1695661 B1 EP 1695661B1 EP 03772935 A EP03772935 A EP 03772935A EP 03772935 A EP03772935 A EP 03772935A EP 1695661 B1 EP1695661 B1 EP 1695661B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- radiofrequency
- frequency
- processor
- therapy
- diagnosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000005481 NMR spectroscopy Methods 0.000 title claims abstract description 37
- 230000005855 radiation Effects 0.000 claims abstract description 53
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 44
- 238000003745 diagnosis Methods 0.000 claims abstract description 38
- 239000011159 matrix material Substances 0.000 claims abstract description 7
- 230000007170 pathology Effects 0.000 claims description 33
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 206010020843 Hyperthermia Diseases 0.000 claims description 29
- 230000036031 hyperthermia Effects 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 22
- 230000005670 electromagnetic radiation Effects 0.000 claims description 22
- 230000000007 visual effect Effects 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 2
- 230000024245 cell differentiation Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 45
- 238000011338 personalized therapy Methods 0.000 abstract description 14
- 230000004069 differentiation Effects 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 3
- 230000035899 viability Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 230000009931 harmful effect Effects 0.000 description 15
- 208000030507 AIDS Diseases 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 230000005865 ionizing radiation Effects 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- 230000003211 malignant effect Effects 0.000 description 7
- 239000013076 target substance Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 230000002715 bioenergetic effect Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000003325 tomography Methods 0.000 description 3
- 230000001173 tumoral effect Effects 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000005672 electromagnetic field Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005493 condensed matter Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005610 quantum mechanics Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/02—Radiation therapy using microwaves
- A61N5/04—Radiators for near-field treatment
- A61N5/045—Radiators for near-field treatment specially adapted for treatment inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
Definitions
- This Invention refers to the VPEPN/H-201 "Zero Series Prototype" Apparatus and associated Method that allow to Quantify the Diagnosis and to Selectively manipulate parameters of the Non-ionizing electromagnetic emission, such as: Frequency, Power and Polarity, with the objective of using the aforementioned emission as a Personalized Therapy, to treat, in principle, pathologies generically identified as Cancer and HIV/AIDS.
- NMR Nuclear Magnetic Resonance
- VPEPN/H-201 Apparatus represents what would be a "Zero Series Prototype" of a Nuclear Magnetic Resonance (NMR) Apparatus of imprecise origin (manufacturer) which, assigned to the conceptual and functional benefits of this invention, is able to operate as required, in the modalities identified as Quantitative Diagnosis and Personalized Therapy.
- NMR Nuclear Magnetic Resonance
- the aforementioned apparatus and its associated method "somehow" manipulates the above mentioned Ionizing radiation, but only at the level of the total amount of radiations that form part of the emission as a whole the emission in a given moment, but NOT in a Selective and separate way, which is the particular and distinctive case of this Invention.
- patent request no. 1361418 of China published on July 31, 2002. by Qiu Jianqin and collaborators, which protects a control panel for a Nuclear Magnetic Resonance (NMR).
- NMR Nuclear Magnetic Resonance
- Apparatus that operates using Radio frequencies (RF) and makes a multiple direct sampling of the Variable Frequency; the design of the United States of America USD 457885 S, for Matsumura Kiyoshi and collaborators, published on May 28, 2002, for an exploratory Apparatus for tomography by means of Nuclear Magnetic Resonance (NMR); another Apparatus is protected by patent no.
- RF Radio frequencies
- Hyperthermia is a problem associated to all radiation Therapies used nowadays; however, there are documents, in the state of the technique or in the state of the art, that refer to the problem, for example, patents of the United States of America numbers 5.441.532 and 5.251.645 for Fenn , published on August 15, 1995 and October 12, 1993, respectively, protect an assembly of elements in phase with the incident Radiofrequency that causes the heating, the Power of the incident radiation is controlled to avoid excessive heating where it is not needed; US 4.819.642 patent for Ndersen and collaborators, published on April 11, 1989 does the same; as well as US 4.702.262 patent for the same inventor, published on October 27, 1987, in which they basically locate the Hyperthermia area.
- the radiation parameters are not Selectively manipulated with the purpose of responding to determined specific requirements that the therapeutic interests, the Bio-Energetic Balance, and/or the particular clinical state of the patient at a determined time may require, due to the existing Conceptual Limitations and current state-of-the-art; in our Scientific proposal we do Selectively and Indistinctly manipulate parameters such as Frequency, Power, and Polarity of Radiation, since they are essential to adequately guarantee the resolution of conceptual, functional and technological limitations, among others, such as the ones mentioned before.
- An objective of this Invention is the exclusive use of Non-Ionizing Electromagnetic Radiation to which parameters such as Frequency, Power and Polarity are selectively manipulated, and the latter, exclusively for the (Personalized) Therapy Modality that shall be applied, in principle, to pathologies such as Cancer and HIV/AIDS.
- Hyperthermia causes in healthy tissue and other tissues that surround the pathology treated with Electromagnetic radiations, whether they are Ionizing or Non-Ionizing.
- Hyperthermia (3) caused by Radiation (R) can be seen in the area surrounding the Pathology (1), this Hyeprthermia causes harmful side effects aside from the problem of Evacuating the Target Substance (7) used from the healthy tissue (2).
- the Pathologic Area (1) is represented being crossed by the Non-Ionizing Electromagnetic radiation (r) with a Resonance Frequency (f 1 ) and the respective and necessary Power value (P 1 ) that will destroy it.
- a Thermal Dissipation (8) irradiation
- a Positive Polarity (Pol 1 ) is assumed as an indication of Energy Contribution.
- the Pathology (1) is represented and the Healthy Surrounding Area (2) not affected by Hyperthermia (3) being crossed by the Non-Ionizing Electromagnetic Radiation (R) in the Resonance Frequency (f 2 ) and its respective and necessary Power value (P 2 ) and Alternate Polarity (Pol 2 ) (in this hypothetical case), which shall Contribute or Yield Energy to this area (2) and this, in direct function with the Therapeutic interests and/or the Bioenergetic Balance.
- R Non-Ionizing Electromagnetic Radiation
- f 2 Resonance Frequency
- P 2 Power value
- Poly 2 Alternate Polarity
- R 1 is the Radiation that acts on the healthy tissue
- R 2 is the Radiation that acts on the Patology
- This Invention is represented to "exemplify", through the VPEPN/H-201 "Zero Series Prototype" Apparatus and associated Method which allows to Selectively manipulate parameters such as Frequency, Power and Polarity of the radiation that will be used as a Therapy and that will affect an area previously identified and localized as an area of Threapeutic interest; the Apparatus aside from Quantifying the Resonance Frequency of different cellular compositions, shall then guarrantee a Quantitative Diagnostic which undeniably conditions the application of a Personalized Therapy that has no precedents in the medical practice, as well as significatively improving Diagnosis as an independent modality.
- the procedure begins by using the technique traditionally known as Nuclear Magentic Resonance (NMR) in use at present, obtaining in this way an image of the area affected by the pathology (Qualitative Diagnosis), once the image generated by the area studied is obtained in its phase of return to equilibrium and having established with it the adequate interconnection to the Frequency Processor (17) of Illustration 17, the Frequency Matrix Monitor (25) that provides reliable and exact information of the specific values of the Resonance Frequencies localized in the different areas studied, in this Monitor, we can accurately see the specific values of the Resonance Frequencies, the Frequency Image Monitor (26) with which the images are obtained in function of the specific net Frequency of each tissue, organ and or system being studied, we shall then get with the aforementioned device, and only at that moment, a graphic Profile of the Frequencies of the studied area, aside from the traditional "mute" images that can be obtained to (Qualitatively) Diagnose due to the limited options given by the state of the technique or the state of the art at this time.
- the Conventional Image Monitor (24) only provides information at a Qualitative level, which implies an Empirical Diagnosis, but this is also a valuable information that provides images that are a direct function of the density of tissues that would be integrated to the other previously mentioned data (visual and value graphs).
- the information obtained is an Electromagnetic Profile of Resonance Frequencies that provides accurate information both for Diagnosis and for Therapy, this procedure which favors the present medical practice for treating pathologies generically identified as Cancer and HIV/AIDS, in principle.
- the Manual Control Digital Filter/Selector is manipulated (18) to make a step by step scanning and analysis depending on the therapeutic requirements of the studied area, to accurately determine and define the Useful Work Resonance Frequencies (UWRF) and their respective Power and Polarity values, being the aforementioned parameters essential for obtaining first the Quantitative Diagnosis, and second to guarantee the later application of the aforementioned Personalized Therapy, as established by the Methodology proposed in the Invention.
- UWRF Useful Work Resonance Frequencies
- the Conventional Image Monitor (24), the Frequency Matrix Monitor (25) and the Frequency Image Monitor (26) help the operator see the evolution of the treatment in the area object of Therapy.
- Radiofrequency emission would be again characterized by the fact that the parameters of the emission such as Frequency, Power and Polarity would be integrated as a whole, and exclusively circumscribed to the functional criteria and design ranges of the Apparatus object of this Invention; i. e., that the Radiofrequency emission behaves as an Indivisible and Unifunctional Electromagnetic beam, in which the parameters that form said electromagnetic beam as a whole are not partially or totally variable at any moment.
- a "re-arrangement" by means of the Non-Ionizing Electromagnetic Radiation, of the cells that were catalogued as malignant is achieved, guarranteeing the absorption and/or yield of energy by the healthy and diseased cells, following a case-specific criteria associated to the specific and particular modification of some of the work parameters that form said radiations, acquiring in this way, Specific and Selective effects on healthy or diseased cells.
- Beams of Non-Ionizing electromagnetic radiations with specific objectives independent from each other are used.
- the cells catalogued as malignant cannot reach (gradually or not) the appropriate energy levels to guarrantee their existence.
- the healthy cells will have the real possibility of revitalizing their functions up to certain limits and thus, they may play their specific biological role in a more efficient way, which in itself implies a recovery and therefore, the conditions for what we call cellular "re-arrangement" are established.
- R-2 Simple Therapy a Dual Electromagnetic Field
- a thermal contribution that destroys them shall be conditioned modifying the values of the Power of the electromagnetic emission that affects the tissue identified as malignant above the normal limits of tolerance and for the case of the surrounding tissue, the Power is maintained in the range of values used for the Diagnosis Modality.
- the Modality identified as R-2 Simple Therapy is suggested to treat pathologies such as HIV/AIDS and Leukemia.
- R-2 Simple Therapy is shown in illustrations 5 and 7.
- the Electromagnetic Field aimed to the malignant cells will be of a Continuous and Non-Pulsating nature; in this way, the harmful effect with a greater range is guarranteed and the cells to which it is destined have few or no possibilities of survival.
- the viral nucleus of HIV/AIDS can be precisely and accurately entered, this nucleus is in most cases very protected; hence, until now, it has been immune to the different treatments to which it has been put through.
- Illustration 1 shows the effect caused by an incident beam of Ionizing radiation of the previous technique, where it can be seen that the area of action of the Ionizing radiation affects the pathogenic tissue and in the same way the surrounding healthy tissue is affected where a harmful area of Hyperthermia is also generated around the pathology.
- the treatment with Ionizing radiation affects all the tissue it crosses generating harmful side effects of different range and nature.
- Illustration 2 a shows the effect of a No-Ionizing radiation without "Target” Substance but it does not inhibit or affect the tumoral tissue since the Frequency of the incident radiation does not make the diseased tissue Resonate and in consequence an area of Hyperthermia is not generated around it.
- the Frequency of the incident radiation interacts with the tumoral tissue, making it resonate, and as a result a surrounding area of Hyperthermia is generated with the consequent harmful side effects on the surrounding healthy tissue.
- Illustration 4 shows the areas of interest in Therapy with radiation of an area affected by a tumor, where the reference (1) represents the Pathological Area; area (2) is a Healthy Tissue that is partially affected by Hyperthermia pictured inside the dotted circle (3); reference (4) indicates the route of the incident radiation in the tissue that is potentially affected by it; reference (5) represents the potential Evacuation of the denominated "Target" Substance.
- Illustration 5 represents a pathological area that is crossed by a Non-Ionizing Electromagnetic Radiation that makes the pathology resonate and absorb the necessary and sufficient amount of energy to guarantee its destruction; the Hyperthermia generated by the above mentioned concept, will be solved a posteriori.
- the radiation that makes the pathogenic tissue has a Frequency (f 1 ), Power (P 1 ) and Polarity (Pol 1 ).
- the Frequency (f 1 ) is specific for that pathogenic tissue.
- said Resonance Frequency is exactly measured and once it has been identified, this Invention also provides the necessary and sufficient technological resources that allow the modification of Power and Polarity of the incident radiation at will, depending on the therapeutic interests, in such a way that it is possible to rehabilitate or destroy the area identified as pathogenic.
- Illustration 6 represents the incident radiation beam in the area of Hyperthermia with Frequency (f3), Power (P3) and Polarity (Pol3); which drags the excess heat emitted by the tumoral tissue that in a way is being rehabilitated or destroyed depending on the case, and consequently cooling the surrounding area affected by Hyperthermia.
- Frequency (f3) was previously identified with the technique proposed in this Invention, as well as the rest of the procedure to be applied to Selectively modify or not Power and Polarity depending on the therapeutic interests.
- the Resonance Frequency of a distant healthy surrounding area that has not been affected by Hyperthermia (III. 7) can be identified and a Non-Ionizing Electromagnetic Radiation can be aimed, with a Resonance Frequency (f 2 ) and its respective values of Power (P 2 ) and Polarity (Pol 2 ); this radiation will emit or absorb energy to this area depending on the therapeutic requirements and/or with the purpose of maintaining the Bio-energetic Balance in this area. In this hypothetical case an alternate Polarity of the incident radiation is assumed.
- NMR Nuclear Magnetic Resonance equipment
- Illustration 11 shows the Simplified Functional Diagram of the Nuclear Magnetic Resonance (NMR) system of this invention, called VPEPN/H-201 "Zero Series Prototype" Apparatus, where the List/Description of the Devices and/or Parts would be the following:
- the proposed VPEPNIH-201 "Zero Series Prototype" Apparatus works exclusively with Non-Ionizing Electromagnetic Radiations, which are selectively manipulated for their application in the Modality of Personalized Therapy only; this Therapy does not generate harmful side effects of any kind to the surrounding healthy tissues. It can be applied to the different presentations and/or manifestations of pathologies in different organs, tissues and/or systems whether in a so-called latent state or in the phase of evident clinical manifestation.
- the Therapy is innocuous as a whole since it does not cause harmful side effects (for example, it does not affect in any way the Nervous and Immune Systems); it significatively reduces the time that passes between Diagnosis, Therapy and Recovery of the patient; the Empiricism that at the moment characterizes the Diagnosis and Therapy Modalities is annulled, except for those Diagnoses where physical-chemical analysis are used and that complement the biopsies and the different test Modalities used to diagnose the HIV/AIDS.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- High Energy & Nuclear Physics (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Signal Processing (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
Description
- This Invention refers to the VPEPN/H-201 "Zero Series Prototype" Apparatus and associated Method that allow to Quantify the Diagnosis and to Selectively manipulate parameters of the Non-ionizing electromagnetic emission, such as: Frequency, Power and Polarity, with the objective of using the aforementioned emission as a Personalized Therapy, to treat, in principle, pathologies generically identified as Cancer and HIV/AIDS. Meaning that the Apparatus integrates in itself the modalities of Diagnosis and Therapy, uses exclusively Non-ionizing electromagnetic radiation and is based theoretically and functionally on the Physical Principle of Resonance and in particular on the principle known as Nuclear Magnetic Resonance (NMR), contributing the following important innovative elements: the Quantification of the Diagnosis and the Selective Manipulation of some of the parameters that intrinsically form part of the electromagnetic emissions of subject, and that, we reiterate, for the modality of personalized therapy specifically.
- We want to make known as a special explanation, that the aforementioned VPEPN/H-201 Apparatus, represents what would be a "Zero Series Prototype" of a Nuclear Magnetic Resonance (NMR) Apparatus of imprecise origin (manufacturer) which, assigned to the conceptual and functional benefits of this invention, is able to operate as required, in the modalities identified as Quantitative Diagnosis and Personalized Therapy.
- That the manufacturers can implement the invention in the production lines in use, generating as a consequence, new Apparatuses with this innovative functional duality of Quantitative Diagnosis and Personalized Therapy, that has been improved, in addition; but the Invention can also be implemented, to the compatible technological methods in use, whether adding the option of Quantitative Diagnosis only, or adding to the previous one, the Personalized Therapy proposed in the Invention.
- In the process of mummification, the Egyptians used, perhaps empirically, a combination of Complementary Radiations and Chemical Compounds to make the preservation of bodies more effective; in the 18th century, around 1774, the German Professor, Franz Anton Mesmer (1734-1815), developed his own theory that generated a current of followers of what was known at the time as "Mesmerism", using Magnetism as a Therapeutic Method for different types of pathologies; by 1845, Michael Faraday (England), researched the Magnetic Properties of dry blood; by 1897, the physicist J. J. Thomson, of Cambridge University (England), discovered the Electron. During the following two decades a series of outstanding physicists among which Max Planck, Ernest Rutherford, Niels Böhr, Erwin Schrodinger and Werner Heisenberg are included, based their research on the work of each other to advance in the study of the structure and properties of the Atom and the Atomic Particles, with this, they revolutionized Physics and elaborated a new theory and language known as Quantum Mechanics; in the early 20th century, the Russian Engineer George Lahkhovsky, used Non-Ionizing Electromagnetic radiations without Complementary Substances, in order to treat different types of Tumors; in 1936 Linus Pauling and Charles D. Coryell discovered that the Magnetic State of hemoglobin changed depending on its state of oxigenation; in 1937 Isidor Isaac Rabi and his colleagues developed the Molecular Beam Magnetic Resonance by passing a beam of lithium chloride molecules through a Magnetic field and then subjecting it to Radio waves; in 1945 and only three weeks apart, the research groups directed by Edward Purcell and Felix Bloch independently proved the phenomenon known as "Nuclear Magnetic Resonance of Condensed Matter"; in 1948 Nicolaas Bloembergen, Edward Purcell and Robert Pound published a paper on "Nuclear Magnetic Relaxation"; in 1949 Erwin Hahn discovered the Spin Echo Phenomenon in the measurements of Nuclear Magnetic Resonance (NMR); in the late 1950's, Russell Varian, of Varian Associates, proposed a new Impulse Method called Nuclear Magnetic Resonance (NMR) with Fourier Transform. Practically at the same time, Irving Lowe and Richard Norberg, both from the University of Washington in Saint Louis, theoretically and experimentally demonstrated how to obtain all the available results of the experiments with Continuous Wave through the Mathematical Manipulation of the Signals produced in an experiment with Impulses. However, at that moment this Mathematical Process necessary to analyze the data of the Impulses (a technique called Fourier Transformation) was not practical (Viable) due to the limitations of the computer equipment of the time; in the 1960's Richard Ernst and Weston Anderson applied the Fourier Analysis to the Impulse Signals to increase the sensitivity of Nuclear Magnetic Resonance; in the second half of the 20th century. Antoine Priore, an Italian electronic technician, developed a therapeutic proposal using Non-Ionizing Electromagnetic Radiation without using Complementary Substances to treat different types of Tumors; in 1969 Raymond Damadian, a physician at the Medical Downstate Center of Brooklyn (New York), began to devise the way of using this technique to detect the first signs of Cancer in the body. In an experiment made in 1970, he extirpated a series of fast growing Tumors that had been implanted in laboratory rats and proved that the Nuclear Magnetic Resonance (NMR) of the Tumors was different to NMRs of normal tissue. In 1971 he published the results of his experiments in "Science" magazine although the Clinical Reliability of his Method had not yet been proved for the Detection or Diagnosis of Cancer; in 1971 Godfrey Hounsfield built the first Computerized Tomography Scanner, which is the base of almost all the imaging systems used nowadays; in 1972 Paul Lauterbur combined the idea of the Gradient with the one of the Computerized Tomography Scanner to make several projections and to reconstruct them to obtain the first Magnetic Resonance image (MRI); in 1976 Peter Mansfield conceived the Echoplanar Technique, which can explore all the brain in a few seconds and in the same year he and his English colleagues, published the first image of a human finger obtained by Magnetic Resonance (MR); in the 1980's Russian Scientists used the combination of Non-Ionizing Electromagnetic radiations with Complementary Substances denominated "Target Substances" as a Therapy against Tumors; in 1990 Seiji Ogawa detected variations in the oxigenation of the local tissue using contrast media that depended on the oxygen level of blood; in the 1990's German Scientists developed the Proposal of the Russian Academicians, using "Nano-particles" as "Target Substances" in combination with Non-Ionizing electromagnetic radiations to treat different types of Tumors; by the late of 1990's Professor Panos Pappas (Greece) presented a therapeutic proposal denominated "PAPIMI" in which he used Non-Ionizing Electromagnetic Radiations without using Complementary Substances to treat different types of Tumors; in 1992 John W. Belliveau, Peter Bandettini and Seiji Ogawa independently published their studies on the cerebral answer to sensorial stimulation, for which images obtained by Magnetic Functional Resonance (MFR) were used and in October, 2003 Paul Lauterbur (American) and Peter Mansfield (British) were awarded the Nobel prize in Medicine for their fundamental discoveries related to the use of Nuclear Magnetic Resonance (NMR), which lead to the development of a modem system that produces three-dimensional images of the organs inside the human body.
- In the state of the technique, there are several Apparatuses and/or Methods for the Diagnosis and Therapy of both Cancer and HIV/AIDS. In the case of Cancer, there are problems of Empiricism problems associated to the Diagnosis. The Apparatuses and Methods associated to the Diagnosis of Cancer through Images, only provide a "mute" Image of the pathology object of study; i. e., they provide a Qualitative Diagnosis, that does not express anything specifically, thus the level of Empiricism in the clinical interpretation of the images obtained continues and through Biopsies can a Diagnosis with a high index of certainty be obtained. For HIV/AIDS we consider that the available options of Diagnosis in use at the moment are adequate and reliable.
- In the field of Cancer Therapy, there are different approaches such as Chemotherapy that uses chemical compounds generically identified as Cytostatic and Non-Cytostatisc drugs, Radiotherapy that uses Ionizing radiations in more than 90% of the therapeutic applications and, in the field of Non-Ionizing radiations, that area of research is practically and mainly in an experimental phase; in both cases (Ionizing and Non-Ionizing radiations) the levels of Selectivity and/or Differentiation are practically null, thus, the index of Empiricim is high.
- For Patentability effects, the Registration of the Linear Particle Accelerator -an apparatus whose fundamental contribution is to eliminate certain limitations of the radiations used in "Conventional Radiotherapy" (with Ionizing Electromagnetic radiation), such as: low propagation speed. insignificant penetrability, etc.— was accepted by all the International Scientific Community and by institutions such as the World Intellectual Property Organization (WIPO).
- The aforementioned apparatus and its associated method "somehow" manipulates the above mentioned Ionizing radiation, but only at the level of the total amount of radiations that form part of the emission as a whole the emission in a given moment, but NOT in a Selective and separate way, which is the particular and distinctive case of this Invention.
- Our Scientific and Technical proposal in the sense Selectively manipulating the parameters that conform the electromagnetic emissions of therapeutic interest such as Frequency, Power and Polarity, is without doubt of a greater Conceptual and Practical scope and it is duly guaranteed with the Prospective Integral Functional Profile that our proposal unobjectionably has in opposition of other Magnetic Resonance Systems and/or Apparatuses not related to the medical profile and the indistinct and/or respective Methods associated to the same.
- Surgery is another additional or complementary therapeutic option, with the well-known adverse effects surgery has in itself.
- In the case of the above mentioned therapeutic options destined to Cancer, we want to make known that these options are applied separately and/or in combination, depending on each particular case, and that for the specific case of HIV/AIDS the totality of therapeutic options offered at the moment are based on Vaccine Candidates (preferably through the administration of so called Vaccine Cocktails which are deemed more effective) and other pharmacological candidates such as interferons, monoclonal antibodies, etc. that can be combined or not with vaccines, and this, in direct function of the clinical state of each particular case.
- In the group of Apparatuses, patent request no.
1361418 of China, published on July 31, 2002. by Qiu Jianqin and collaborators, which protects a control panel for a Nuclear Magnetic Resonance (NMR). Apparatus that operates using Radio frequencies (RF) and makes a multiple direct sampling of the Variable Frequency; the design of the United States of America USD 457885 S, for Matsumura Kiyoshi and collaborators, published on May 28, 2002, for an exploratory Apparatus for tomography by means of Nuclear Magnetic Resonance (NMR); another Apparatus is protected by patent no.5.736.858 of the United States of America, for Katznelson and collaborators, published on April 7, 1998, that deals with a complete body of gradient coils that obtains ultra-fast images; another similar patent isU.S. no. 5.530.355 , for Doty and collaborators, published on June 25, 1996, that protects a transversal gradient coil Apparatus that provides a Magnetic Resonance (MR) image. - For the Diagnosis, there is the use of imaging contrast agents in the state of technique, as is the case of international application
WO 03013616, for Mainero Valentino US2002121898, for Brevard Christian and collaborators, published on September 5, 2002, contains an excitation circuit and a test that measures and recovers the return signal emitted by the Nuclear Magnetic Resonance (NMR) Apparatus; patent no:5.590.656 of the United States of America, for O'Dorisio and collaborators, published on January 7, 1997, describes and protects the use of radio tracers as markers of the tissues of pathologies, this Method includes the administration of a radio tracer and also a test of radiation detection; patent no.5.596.992 of the United States of America, for Haaland and collaborators, published on January 28, 1997, covers the classification of cancerous tissue by infrared radiation; patent no.5.579.773 of the United States of America, for Vo-Dinh and collaborators deals with an Apparatus and Method for the Diagnosis of Cancer using a laser; patents nos.5.420.510 ,5.404.882 and5.281.917 of the United States of America, and European patentEP 0234524 , talk about Methods that use images to diagnose Cancer. - For the Diagnosis of pathologies like Cancer, there are documents in the state of the technique or state of the art that report the use of the Apparatus and Method to improve the Diagnosis of Cancer; for example, the patent of the United States of America no.
6.535.755, for Ehnholm , published on March 18, 2003, that protects the Apparatus and Method to increase the signal/noise ratio of a Nuclear Magnetic Resonance (NMR) signal, with which the temperature of the operation of the treatment of Cancer is controlled; patent of the United States of America no.5.885.547, for Gray and collaborators, published on March 23, 1999, describes a Cancer Therapy that uses internal radionuclides that emit beta and gamma radiation; patent of the United States of America no.5.596.619 for Carol , published on January 21, 1997, describes an Apparatus and Method for a Therapy using a spatially modulated beam that crosses the tumor; international applicationWO 9620733 5.528.652, for Smith and collaborators, published on June 18, 1996, describes a Cerebral Therapy Method, using Ionizing radiation; application for international patentWO 9412240 EP 0562644, for Nunan Craig and collaborators, published on September 29,1993, refers to an Apparatus that produces irregular radiation in which the Power of the incident Ionizing radiation is adjusted; patent of the United States of America no.5.231.984, for Santana-Blank , published on August 13, 1993, describes an Apparatus and Method to perform a Laser Therapy on cancerous tissues of the skin; European patentEP 0406454, for Albini Domenico and collaborators, published on January 9, 1991, refers to an Apparatus that performs photochemistry with the aid of a laser; patents of the United States of America numbers4.815.448 and4.815.447, for Mills , published on March 28, 1989, protect a Therapy that uses Selective radiation of Frequencies combined with agents used in Chemotherapy; patent of the United States of America no.4.690.130, for Mirell Stuart , published on September 1, 1987, protects an electromagnetic control system for Chemotherapy; Japanese patentJP 57185220, for Endou Hiroshi - During Ionizing or Non-Ionizing Therapy (and only when the Resonance is obtained), an region of Hyperthermia in the area surrounding the radiated pathology appears; thus, Hyperthermia is a problem associated to all radiation Therapies used nowadays; however, there are documents, in the state of the technique or in the state of the art, that refer to the problem, for example, patents of the United States of America numbers
5.441.532 and5.251.645 for Fenn , published on August 15, 1995 and October 12, 1993, respectively, protect an assembly of elements in phase with the incident Radiofrequency that causes the heating, the Power of the incident radiation is controlled to avoid excessive heating where it is not needed;US 4.819.642 patent for Ndersen and collaborators, published on April 11, 1989 does the same; as well asUS 4.702.262 patent for the same inventor, published on October 27, 1987, in which they basically locate the Hyperthermia area. - From
US-A-5690/09 is known a method of selectively heating targeted cells within a specimen while avoiding heating of non-targeted cells is provided. The method comprises the steps of: - (a) determining at least one combination of magnetic field strength and radio wave frequency (strength-frequency combination) at which only the targeted cent will resonate when the magnetic field and the electromagnetic radiation are applied to the specimen orthogonal to one another; and
- (b) applying a magnetic field and a radio frequency wave to the targeted cells, the strength of the magnetic field and the frequency of the radio wave corresponding to the strength-frequency combination to the targeted cells, in order to cause nuclear magnetic resonance in the targeted cells, thereby increasing the temperature of only the targeted cells.
- We can additionally refer as patents of reference of interest, to the following: EPO patents No.
US 5 690 109 A ,WO 91/07132 A EP 0695560 ,WO 9519841 EP 0198257 ,WO 8804414 EP 0252118 , andWO 8703798 0240990 0305008 0284542 0355760 0340005 0705603 0400940 0512981 0650601 0711121 CH 681356 CH 669733 563137 528476 534533 04102465 4515165 ,4524779 ,4691712 ,4935631 ,5079698 ,5168514 ,5442675 ,5464445 and5609816 . - In all the therapeutic options based on Ionizing and Non-Ionizing radiations currently in use, the radiation parameters are not Selectively manipulated with the purpose of responding to determined specific requirements that the therapeutic interests, the Bio-Energetic Balance, and/or the particular clinical state of the patient at a determined time may require, due to the existing Conceptual Limitations and current state-of-the-art; in our Scientific proposal we do Selectively and Indistinctly manipulate parameters such as Frequency, Power, and Polarity of Radiation, since they are essential to adequately guarantee the resolution of conceptual, functional and technological limitations, among others, such as the ones mentioned before.
- Furthermore, it is very important, to duly recognize the Viability of this invention for the following reasons:
- a) In the Scientific order because all the Principles of Work that support it are perfectly demonstrable at theoretical level.
- b) In the Technical order because we have necessary and sufficient means to integrally implement it in the practical order.
- c) In the Commercial order because the Demand is adequately identified, for an Offer of the scope and making as the one that is the subject of this Invention.
- An objective of this Invention is the exclusive use of Non-Ionizing Electromagnetic Radiation to which parameters such as Frequency, Power and Polarity are selectively manipulated, and the latter, exclusively for the (Personalized) Therapy Modality that shall be applied, in principle, to pathologies such as Cancer and HIV/AIDS.
- It is another objective of the present Invention, to eliminate the level of Empiricism that today distinguishes the Diagnosis and Therapy Modalities, since exact indexes of Selectivity and/or Differentiation are obtained when the Resonance Frequency is quantified for the first time and therefore, the Diagnosis of the Pathology. This achievement unequivocally conditions the ability to knowledgably apply a Personalized Therapy with a scope and making that has no precedents in the medical practice.
- It is still another objective of this Invention, to eliminate the harmful effects Hyperthermia causes in healthy tissue and other tissues that surround the pathology treated with Electromagnetic radiations, whether they are Ionizing or Non-Ionizing.
- It is yet another objective of this Invention to totally avoid the use of the so-called "Target" Substances, avoiding the problems associated to the possible Evacuation of these substances.
- It is also an objective of this Invention to totally eliminate the use of Ionizing radiation both for Diagnosis as well as for Theray Modalities.
- It is an objective of this Invention to avoid the collateral damage caused by Chemotherapy and/or Radiotherapy to the, Nervous and Immune Systems.
- It is another objective of the this Invention to decrease the use of Surgery as a therapeutic option.
- It is also an objective of this Invention to decrease the time that passes between Diagnosis, Therapy and Rehabilitation of the patient.
- It is also an objective of this Invention to provide an Apparatus and associated Method that ca be quickly implemented in the so-called Health Market.
- It is also an objective of this Invention to decrease the high Costs specifically associated to Research and Development "R+D" related to the search of therapeutic options for pathologies like Cancer and HIV/AIDS, among others.
- It is another objective of the this Invention, to provide a Personalized Therapy for the pathologies generically identified as Cancer and HIV/AIDS, among others.
- It is also an objective of the this Invention to definitively annul the harmful effects and consequences that cause Cellular Mutation and overlap, Biological conducts that distinguish, as if they were "Biological Standards", pathologies such as Cancer and HIV/AIDS, among many others.
- It can be seen that in the area of influence of the path (4) of Radiation (R), the Radiation Ionizes (6) the matter it crosses (2), be this Biological or not, aside from generating harmful side effects in the Area Surrounding the Pathology (1) as a product of Hyperthermia (3).
- In this illustration it can be seen the two possible behaviors that can take place:
- 2a) WITHOUT Hyperthermia, in case there is NO hyperthermia caused by Radiation (R), Resonance with the Pathology of reference (1) in all the matter it crosses (2).
- 2b) In the Surrounding Area WITH Hyperthermia (3), if the Radiation (R) Resonates with the Pathology (1) then there is Resonance and the harmful side effect caused by Hyperthermia can be seen on the surrounding Healthy Biological tissue (2).
- Hyperthermia (3) caused by Radiation (R) can be seen in the area surrounding the Pathology (1), this Hyeprthermia causes harmful side effects aside from the problem of Evacuating the Target Substance (7) used from the healthy tissue (2).
- Area affected by the Pathology (1), healty Surrounding Area, (2) Healty Surrounding Area affected by Hyperthermia (3), Tissue and area possibly affected by Radiation (r) in the Area of influence (4). The potential Evacuation (5) of the Target Substance (7) is visualized.
- The Pathologic Area (1) is represented being crossed by the Non-Ionizing Electromagnetic radiation (r) with a Resonance Frequency (f1) and the respective and necessary Power value (P1) that will destroy it. In this case a Thermal Dissipation (8) (irradiation) is generated in the Healty Surrounding Area (2) produced by Hyperthermia. In this hypothetical case a Positive Polarity (Pol1) is assumed as an indication of Energy Contribution.
- It represents the Healty Surrounding Area (2) affected by Hyperthermia (3) being passed through by the Non-Ionizing Electromagnetic Radation (R) in the Resonance Frequency (f3) and its respective Power value (P3) that shall evacuate the Excess Heat yielded by the Pathological Area (1). In this hypothetical case a Negative Polarity (Pol3) is assumed as an indication of Energy Absorption.
- The Pathology (1) is represented and the Healthy Surrounding Area (2) not affected by Hyperthermia (3) being crossed by the Non-Ionizing Electromagnetic Radiation (R) in the Resonance Frequency (f2) and its respective and necessary Power value (P2) and Alternate Polarity (Pol2) (in this hypothetical case), which shall Contribute or Yield Energy to this area (2) and this, in direct function with the Therapeutic interests and/or the Bioenergetic Balance.
- It is the visual integration of ILLUSTRATIONS 5, 6 and 7 in order to have an approximate idea of the concept of "Sequence of Emission Pattern", in this specific hypothetical case; where R1 is the Radiation that acts on the healthy tissue (2), R2 is the Radiation that acts on the Pathology (1) and R3 is the Radiation that solves the problem of Hyperthemia (3). The R-3 Complex Therapy Modality, operates on three different frequencies integrated in the chart of Radiation (R), and this is what better illustrates the Main or Basic Concept of the Scientific Proposal.
-
- Polarity (Pol), where: Pol1 is positive (+)
- Pol2 can be positive (+) or negative (-)
- Pol3 is negative (-)
-
- Polarity (Pol), where: Pol1 is positive (+)
- Pol2 can be positive (+) or negative (-)
- Pol3 is negative (-)
- It represents an Emission of Conventional Radiofrequency that passes through Biological Substances (2) and some of the parameters that compose it, such as Frequency, Power and Polarity, are shown since they were considered of high-priority in our studies and analysis. The Radiations R1, R2 and R3 form a beam that cannot be functionally divisible and in this example the ratio between the fundamental parameters is:
Pol1 = Pol2 = Pol3 (Indeterminate for this example) - In this illustration the fundamental Devices and/or Tehcnologic Parts that make this Invention Viable are shown conceptually and Functionally integrated:
- a) Radiofrecuency Resonating Antenna (4)
- b) Low-Signal Radiofrequency Processor/Modulator (10)
- c) Radiofrequency Pulse Amplifier (13)
- d) Manual Contro Digital Filter/Selector(18)
- e) Central Pulse Control (20)
- f) Frequency Matrix Monitor (25)
- g) Frequency Image Monitor (26)
- h) Control Panel (28)
- It is important to note that without the Conceptual and Functional integration of the above mentioned Devices and/or Parts (Technological Innovations) it would not be possible to attain the objectives and goals achieved with this Invention.
- That the Devices and/or Parts listed in paragraphs (d, f, g, h) are essential to operate the Apparatus in the Quantitative Diagnosis Modality, and that to operate the Apparatus in the Personalized Therapy Modality the former plus the ones listed in paragraphs (a, b, c, e) would be essential.
- This Invention is represented to "exemplify", through the VPEPN/H-201 "Zero Series Prototype" Apparatus and associated Method which allows to Selectively manipulate parameters such as Frequency, Power and Polarity of the radiation that will be used as a Therapy and that will affect an area previously identified and localized as an area of Threapeutic interest; the Apparatus aside from Quantifying the Resonance Frequency of different cellular compositions, shall then guarrantee a Quantitative Diagnostic which undeniably conditions the application of a Personalized Therapy that has no precedents in the medical practice, as well as significatively improving Diagnosis as an independent modality.
- The procedure begins by using the technique traditionally known as Nuclear Magentic Resonance (NMR) in use at present, obtaining in this way an image of the area affected by the pathology (Qualitative Diagnosis), once the image generated by the area studied is obtained in its phase of return to equilibrium and having established with it the adequate interconnection to the Frequency Processor (17) of Illustration 17, the Frequency Matrix Monitor (25) that provides reliable and exact information of the specific values of the Resonance Frequencies localized in the different areas studied, in this Monitor, we can accurately see the specific values of the Resonance Frequencies, the Frequency Image Monitor (26) with which the images are obtained in function of the specific net Frequency of each tissue, organ and or system being studied, we shall then get with the aforementioned device, and only at that moment, a graphic Profile of the Frequencies of the studied area, aside from the traditional "mute" images that can be obtained to (Qualitatively) Diagnose due to the limited options given by the state of the technique or the state of the art at this time.
- The Conventional Image Monitor (24) only provides information at a Qualitative level, which implies an Empirical Diagnosis, but this is also a valuable information that provides images that are a direct function of the density of tissues that would be integrated to the other previously mentioned data (visual and value graphs).
- From the previous, we can infer that the information obtained is an Electromagnetic Profile of Resonance Frequencies that provides accurate information both for Diagnosis and for Therapy, this procedure which favors the present medical practice for treating pathologies generically identified as Cancer and HIV/AIDS, in principle.
- A Modality of Quantitative Diagnosis is proposed, since using the Frequency Matrix Monitor (25) the Specific, Particular and Respective Values of the Resonance Frequencies of the areas of interest are accurately known and the Frequency Image Monitor (26) provides images that are in direct function of the aforementioned Frequencies which provide a graphic, and visual profile of the Frequencies of the studied area and through the Conventional Image Monitor (24), images that are in direct function with the density of the tissues are provided, then under the terms and conditions mentioned before, an Electromagnetic Profile of Integral Resonance Frequencies that conditions the accurate and effective application in sequence of Diagnosis and Therapy, and in this way, a Personalized Therapy that has no precedents in today's medical practice can be implemented.
- With the Control Panel (28) located in the Operator's Console (22) the Manual Control Digital Filter/Selector is manipulated (18) to make a step by step scanning and analysis depending on the therapeutic requirements of the studied area, to accurately determine and define the Useful Work Resonance Frequencies (UWRF) and their respective Power and Polarity values, being the aforementioned parameters essential for obtaining first the Quantitative Diagnosis, and second to guarantee the later application of the aforementioned Personalized Therapy, as established by the Methodology proposed in the Invention.
- The above mentioned parameters (Frequency, Power and Polarity), already selected and modified; i. e. Selectively manipulated in function of the therapeutic interests, are programmed in the Central Computer (20) (
fig 11 ) with the aid of the Keyboard (27) located in the Operator's Console (22), to give the precise instructions to the Central Computer (20) which will send the information to the Pulse Central Control (16) to be analogically processed by the Low Radiofrequency Signal Processor/ Modulator (10) and amplified in the Radiofrequency Pulse Amplifier (13). - The Central Computer (20), the Pulse Central Control (16), the Digital-Analogical Converters (12), the Low Radiofrequency Signal Processor/Modulator (10), the Radiofrequency Pulse Amplifier (13) and the Radiofrecuency Resonating Antenna (4), must be in operation and must have the necessary and sufficient Functional Capacity (Operational) to then handle the "New Personalized Parameters" (modified, previous Selective Manipulation) of Frequency, Polarity and, very specially, Power to next proceed to perform a new of Radiofrequency emission with the aforementioned parameters emitted with the specific objective of using them as a Personalized Therapy. As shown in the disposition of the elements in
Illustration 11, the Conventional Image Monitor (24), the Frequency Matrix Monitor (25) and the Frequency Image Monitor (26) help the operator see the evolution of the treatment in the area object of Therapy. - Once this step is finished, a second Diagnosis is made using the aforesaid traditional procedure, where the generated Radiofrequency emission would be again characterized by the fact that the parameters of the emission such as Frequency, Power and Polarity would be integrated as a whole, and exclusively circumscribed to the functional criteria and design ranges of the Apparatus object of this Invention; i. e., that the Radiofrequency emission behaves as an Indivisible and Unifunctional Electromagnetic beam, in which the parameters that form said electromagnetic beam as a whole are not partially or totally variable at any moment.
- It is evident that the course of action and the specific treatment for the patient will be defined, depending on the results that shall be evaluated by specialized medical personnel.
- In principle, a "re-arrangement", by means of the Non-Ionizing Electromagnetic Radiation, of the cells that were catalogued as malignant is achieved, guarranteeing the absorption and/or yield of energy by the healthy and diseased cells, following a case-specific criteria associated to the specific and particular modification of some of the work parameters that form said radiations, acquiring in this way, Specific and Selective effects on healthy or diseased cells. Beams of Non-Ionizing electromagnetic radiations with specific objectives independent from each other are used.
- By maintaining this cellular "re-arrangement" and its respective level of Bioenergétic Balance, the cells catalogued as malignant cannot reach (gradually or not) the appropriate energy levels to guarrantee their existence. By maintaining their Bioenergetic Levels, the healthy cells will have the real possibility of revitalizing their functions up to certain limits and thus, they may play their specific biological role in a more efficient way, which in itself implies a recovery and therefore, the conditions for what we call cellular "re-arrangement" are established.
- The basis of the Scientific-Technical proposal of this Invention is the application of the Physical Principle of Resonance and in particular the one identified as Nuclear Magnetic Resonance (NMR) by means of the VPEPN/H-201 "Zero Series Prototipe" Apparatus and associated Method since it is only under the condition of Resonance in which the transference of energy in one way or another is materialized; i. e., the yield or absorption of energy. The unequivocal difference in the values of the Resonance Frequencies is the basis for the recognition of the different molecules that form the tissues, and such is precisely the basis of Nuclear Magnetic Resonance (NMR) applied with medical purposes.
- By obtaining the value of the Frequency in which the malignant cellular focus Resonates and also knowing the Resonance Frequency value of the cells of the tissue that surround it, a Dual Electromagnetic Field (R-2 Simple Therapy) is applied in principle, where a thermal contribution that destroys them shall be conditioned, modifying the values of the Power of the electromagnetic emission that affects the tissue identified as malignant above the normal limits of tolerance and for the case of the surrounding tissue, the Power is maintained in the range of values used for the Diagnosis Modality. The Modality identified as R-2 Simple Therapy is suggested to treat pathologies such as HIV/AIDS and Leukemia. R-2 Simple Therapy is shown in illustrations 5 and 7.
- For the case of tumors, the R-3 type Complex Therapy is suggested, this therapy is shown in
Illustration 9. - Depending on the therapeutic interests and in face of the possibility of other pathologies associated and/or concurrent to the main pathology, Therapies that may be necessary and advisable such as R-4 Therapy, R-5 Therapy, among others, can be implemented.
- The evaluation and selection of the Polarity (positive or negative) of the incident radiation is very important and significant since, depending on the Polarity as well as on the interests and objectives desired with respect to the Bioenergetic Balance or Equilibrium, there may be energy absorption or yield. As mentioned before, a Selective application of radiation is needed for each kind or group of malignant cells in a specific and particular way, thus the principle of application of this Invention is the use of different beams of radiation, with precise, exact and specific sequencies and doses, where each is designed and intended for a specific objective (goal), being also independent from the rest. An example is shown in
Illustration 8. - The Electromagnetic Field aimed to the malignant cells, will be of a Continuous and Non-Pulsating nature; in this way, the harmful effect with a greater range is guarranteed and the cells to which it is destined have few or no possibilities of survival.
- According to the technological criteria hereby proposed the viral nucleus of HIV/AIDS can be precisely and accurately entered, this nucleus is in most cases very protected; hence, until now, it has been immune to the different treatments to which it has been put through.
-
Illustration 1, shows the effect caused by an incident beam of Ionizing radiation of the previous technique, where it can be seen that the area of action of the Ionizing radiation affects the pathogenic tissue and in the same way the surrounding healthy tissue is affected where a harmful area of Hyperthermia is also generated around the pathology. The treatment with Ionizing radiation affects all the tissue it crosses generating harmful side effects of different range and nature. - Illustration 2 a shows the effect of a No-Ionizing radiation without "Target" Substance but it does not inhibit or affect the tumoral tissue since the Frequency of the incident radiation does not make the diseased tissue Resonate and in consequence an area of Hyperthermia is not generated around it.
- In illustration 2 b, the Frequency of the incident radiation interacts with the tumoral tissue, making it resonate, and as a result a surrounding area of Hyperthermia is generated with the consequent harmful side effects on the surrounding healthy tissue.
- In
illustration 3, another Modality of Therapy is represented where a "Target" substance is used, the harmful side effect of Hyperthermia can be seen in this illustration, with the addition of the problem of the Evacuation of the "Target substance (represented by the dispersed spots in the healthy tissue) from the body. - Illustration 4, shows the areas of interest in Therapy with radiation of an area affected by a tumor, where the reference (1) represents the Pathological Area; area (2) is a Healthy Tissue that is partially affected by Hyperthermia pictured inside the dotted circle (3); reference (4) indicates the route of the incident radiation in the tissue that is potentially affected by it; reference (5) represents the potential Evacuation of the denominated "Target" Substance.
- Illustration 5, represents a pathological area that is crossed by a Non-Ionizing Electromagnetic Radiation that makes the pathology resonate and absorb the necessary and sufficient amount of energy to guarantee its destruction; the Hyperthermia generated by the above mentioned concept, will be solved a posteriori. The radiation that makes the pathogenic tissue has a Frequency (f1), Power (P1) and Polarity (Pol1). The Frequency (f1) is specific for that pathogenic tissue. In this Invention said Resonance Frequency is exactly measured and once it has been identified, this Invention also provides the necessary and sufficient technological resources that allow the modification of Power and Polarity of the incident radiation at will, depending on the therapeutic interests, in such a way that it is possible to rehabilitate or destroy the area identified as pathogenic.
- Illustration 6, represents the incident radiation beam in the area of Hyperthermia with Frequency (f3), Power (P3) and Polarity (Pol3); which drags the excess heat emitted by the tumoral tissue that in a way is being rehabilitated or destroyed depending on the case, and consequently cooling the surrounding area affected by Hyperthermia. In this hypothetical case a negative Polarity of the incident radiation as an indication of absorption of energy is assumed. It is clarified that the Frequency (f3) was previously identified with the technique proposed in this Invention, as well as the rest of the procedure to be applied to Selectively modify or not Power and Polarity depending on the therapeutic interests.
- In addition, with the knowledge of this Invention, the Resonance Frequency of a distant healthy surrounding area that has not been affected by Hyperthermia (III. 7) can be identified and a Non-Ionizing Electromagnetic Radiation can be aimed, with a Resonance Frequency (f2) and its respective values of Power (P2) and Polarity (Pol2); this radiation will emit or absorb energy to this area depending on the therapeutic requirements and/or with the purpose of maintaining the Bio-energetic Balance in this area. In this hypothetical case an alternate Polarity of the incident radiation is assumed.
- It is important to note that the Sequence of the Emission Pattern of the Non-Ionizing Electromagnetic Radiation must guarantee: the harmful effect with the highest range allowed on the pathogenic tissue so that the malignant cells that compose it have slight or no possibilities of survival; that it can adequately solve the Hyperthermia problem, and avoid all types of harmful side damage on the healthy tissue surrounding the pathology object of Therapy, as well as on the Nervous and Immune Systems.
Illustration 8 represents the visual integration of the beams of illlustrations 5, 6 and 7 that form a single Emission Sequence and where the behavior or ratio of the values of Frequency (f), Power (p) and Polarity (Pol) fulfill the following ratios: - Polarity (Pol)
- Pol1 is positive (+)
- Pol2 is positive (+) or negative (-)
- Pol3 is negative (-)
-
Illustration 9 represents the hypothetical graphs of the Basic or Main Principle of Work of this Invention, note the continuous beam emission sequence used in this particular case in the Modality of R-3 Complex Therapy where the behavior or ratio of parameters such as Frequency, Power and Polarity, fulfill the following ratios: - Polarity (Pol)
- Pol1 is positive (+)
- Pol2 is positive (+) or negative (-)
- Pol3 is negative (-)
- Conventional Nuclear Magnetic Resonance equipment (NMR) emits a Radiofrequency beam in which parameters such as Frequency, Power and Polarity that compose it are constant in their respective values; i. e., the subject beam is displayed as a set of indivisible and "unifunctional" radiations as well.
Illustration 10 shows three (3) beams with different frequencies but equal Power and an indeterminate Polarity of equal signs. The ratio of the parameters is as follows: - Pol1 Indeterminate
- Pol2 Indeterminate
- Pol3 Indeterminate
-
Illustration 11 shows the Simplified Functional Diagram of the Nuclear Magnetic Resonance (NMR) system of this invention, called VPEPN/H-201 "Zero Series Prototype" Apparatus, where the List/Description of the Devices and/or Parts would be the following: - 1) Magnet with incorporated cooling system and Isolation for the Assembly
- 2) Shim coil system
- 3) Gradient system coil
- 4) RF resonator antenna
- 5) Patient table
- 6) Transmit - Receive Selector
- 7) Preamplifier
- 8) Radiofrequency and magnetic-proof leadthroughs
- 9) Radiofrequency low signal processor / Quadrature demodulator with low-pass filters
- 10) Radiofrequency low signal processor / Modulator
- 11) Analog-Digital Converter (ADC)
- 12) Digital -Analog Converter (DAC)
- 13) Radiofrequency pulse amplifier
- 14) Gradient amplifiers X, Y, Z with Digital-Analog Converters
- 15) Magnet power supply
- 16) Central pulse control
- 17) Frequency Processor
- 18) Manual Control Digital Filter/Selector
- 19) Image Processor
- 20) Central Computer
- 21) Image Storage
- 22) Operator's Console
- 23) Protocol Monitor
- 24) Conventional-Image Monitor
- 25) Frequency Matrix Monitor
- 26) Frequency Image Monitor
- 27) Keyboard
- 28) Control Panel.
- The proposed VPEPNIH-201 "Zero Series Prototype" Apparatus works exclusively with Non-Ionizing Electromagnetic Radiations, which are selectively manipulated for their application in the Modality of Personalized Therapy only; this Therapy does not generate harmful side effects of any kind to the surrounding healthy tissues. It can be applied to the different presentations and/or manifestations of pathologies in different organs, tissues and/or systems whether in a so-called latent state or in the phase of evident clinical manifestation.
- With the use of this Invention, exact indexes of Selectivity and/or Differentiation that allow making a Quantitative Diagnosis and an effective and Customized Therapy are achieved; it annuls the so-called Hyperthermia effect, caused by all types of radiation used in the state of the technique or in the state of the art for the Therapy Modality, and because it is applied in "Real Time" it nulifies the effects of Overlapping and Cellular Mutability inherent in all living beings as a natural mechanism for survival. The presentation of the so-called "drug resistance" as a natural mechanism for survival of certain pathologies is categorically discarded, since this Invention does not propose the use of drugs as a fundamental part of or as a complement to this Therapy and it only uses Non-Ionizing Electromagnetic Radiations which are adjusted on-line to the evolutive stage of the pathology being treated. In the innovating proposal of this Invention, Non-Ionizing electromagnetic radiations are used instead of Ionizing Radiations, the so-called "Target" Substances are also not used, thus avoiding the problems associated with the Evacuation of these substances from the body.
- The Therapy is innocuous as a whole since it does not cause harmful side effects (for example, it does not affect in any way the Nervous and Immune Systems); it significatively reduces the time that passes between Diagnosis, Therapy and Recovery of the patient; the Empiricism that at the moment characterizes the Diagnosis and Therapy Modalities is annulled, except for those Diagnoses where physical-chemical analysis are used and that complement the biopsies and the different test Modalities used to diagnose the HIV/AIDS.
- It significatively reduces the Costs of Research and Development (R+D), as well as those of welfare services.
- The Dosimetry Calculation procedures are significantly simplified and they are now exact.
- It is a non-invasive application that considerably limits the use of Surgery as a therapeutic modality.
- The following Table establishes a comparison, at a qualitative level, between the Existing Technologies (state-of-the-art) and the Technology contained in our Invention so that the potential scope of our Invention can be accurately appraised.
CHARACTERISTICS TO ANALIZE AND COMPARE PREVIOUS TECHNOLOGY PROPOSED TECHNOLOGY DIAGNOSTIC THERAPY DIAGNOSTIC THERAPY CANCER HIV/Aids CANCER HIV/Aids CANCER HIV/Aids CANCER HIV/Aids 1 Selectivity and/or Differentiation Only on Qualitative level Solved With Empiricism NO Solved With Quantitative Modality Introduce Quantitative Modality Solved With Quantitative Modality Solved With Quantitative Modality 2 Cellular Overlap not covered not covered Not Solved Not Solved Solved Solved Solved Solved 3 Cellular Mutability not covered not covered Not Solved Not Solved Solved Solved Solved Solved 4 Types of Radiations employed Non-Ionizing Physical-Chemical Analysis Ionizing >>> Non-Ionizing Only on a Pharmacological basis Non Ionizing Non-Ionizing + existent Non-Ionizing Non-Ionizing 5 "Target Substance" EVACUATION Eventually No In some cases No NO NO NO NO 6 Hyperthermia Eventually No Yes No Eventually Eventually, with low impact Solved Very Low impact 7 Drug Resistance (in function of #3) No No Very High Yes (100%) Yes (100%) NO NO NO NO 8 Harmful Side (in function of # 1) Effects Relative Undefined Yes Very Important Undefined NO NO NO NEO 9 Index of Empiricism (in function of # 1) Very High Soled High Very High NO NO NO NO 10 Surgery (See implications) Eventually No Frequently No NO NO NO NO 11 "R+D" Costs High Relative Low Very High Excessively High Very Low Very Low Very Low Very Low 12 Implementation on the Health Market On Long Term On Long Term On Long Term On Long Term On Short Term On Short Term Term On Short Term 13 Operational Phase of the Project On Long Term On Long Term On Long Term On Long Term On Short Term On Short Term On Short Term On Short Term - Specific Modalities of this Invention have been illustrated and described, it will be obvious for those expert in the technique and/or the art, that several modifications or changes can be made without leaving the scope of the Invention. We shall attempt to cover the aforementioned, within the aggregated claims so that all the changes and modifications fall within the scope of this Invention.
Claims (2)
- A nuclear magnetic resonance apparatus integrating both the modalities of diagnosis and personalised therapy in order to quantify diagnosis as well as to treat pathologies including those generically identified as cancer comprising:a magnet with a cooling system and isolation (1), a shim coil system (2), a gradient coil system (3), and a radiofrequency resonator antenna (4) connected to the magnet, a patient table (5), a transmit-receive selector (6) connected to the radiofrequency resonator antenna; a preamplifier (7) connected to the transmit-receive selector (6), radiofrequency and magnetic-proof leadthroughs (8), a radiofrequency low signal processor/quadrature demodulator (9) with low-pass filters connected through the leadthroughs (8) to the preamplifier (7), a low signal radiofrequency processor/modulator (10) connected to the radiofrequency low signal processor/quadrature demodulator (9), a radiofrequency pulse amplifier (13) connected to the modulator (10) and to the transmit-receive selector (6) through the leadthroughs 8, a magnet power supply (15) connected to the magnet (1) and to the shim coil system (2) through the leadthroughs (8), a central pulse control (16) connected to the radiofrequency low signal processor/quadrature demodulator (9), and also to the low signal radiofrequency processor/modulator (10) by means of analog-digital converters (12), gradient amplifiers X, Y, Z (14) connected by means of digital-analog converters (12) to the central pulse control (16), a central computer (20), an image Processor (19) connected to the central computer (20), the image processor (19) also being connected to a frequency processor (17), a keyboard (27) connected to the central computer (20), an image Storage (21) connected to the central computer (20), an operator's console (22), a protocol monitor (23) connected to the computer (20), an image monitor (24) connected to the image processor (19), the frequency processor (17) also connected to the pulse control (16) and to the demodulator (9) by means of analog-digital convertors (11), a controlled digital filter/selector (18) connected to the frequency processor (17), a control panel (28) connected to the controlled filter/selector (18), a frequency matrix monitor (25) for providing information of the values of the resonance frequencies localised in the area studied connected to the frequency processor (17), and a frequency image monitor (26) for providing a graphic and visual profile of the resonant frequencies of the studied area connected to the frequency processor (17), wherein the radiofrequency resonation antenna (4), the low signal radiofrequency processor/modulator (10), the radiofrequency pulse amplifier (13), and the central pulse control (16) are adapted for selectively manipulating non-ionizing electromagnetic radiation in order to personalize therapy which treats said pathologies
- The nuclear magnetic resonance apparatus of claim 1, wherein the apparatus provides an electromagnetic radiation beam with selectiveness and cellular differentiation for therapy by using the radiofrequency resonator antennas (4), the low signal radiofrequency processor/modulator (10), the radiofrequency pulse amplifier (13), and the central pulse control (16), so that the radiation beam - with new values of the previously and selectively modified parameters such as the useful resonance frequencies (FRUT) as well as their power and polarity values - selectively destroys the detected pathologies while annulling hyperthermia in the surroundings of the treated area.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/MX2003/000105 WO2004098408A1 (en) | 2003-11-28 | 2003-11-28 | Nuclear magnetic resonance device |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1695661A1 EP1695661A1 (en) | 2006-08-30 |
EP1695661B1 true EP1695661B1 (en) | 2012-04-18 |
Family
ID=33432482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03772935A Expired - Lifetime EP1695661B1 (en) | 2003-11-28 | 2003-11-28 | Nuclear magnetic resonance device |
Country Status (12)
Country | Link |
---|---|
US (1) | US7423429B2 (en) |
EP (1) | EP1695661B1 (en) |
JP (1) | JP2007528231A (en) |
KR (1) | KR100929545B1 (en) |
CN (1) | CN1878498B (en) |
AT (1) | ATE553697T1 (en) |
AU (1) | AU2003279601A1 (en) |
CA (1) | CA2587828C (en) |
ES (1) | ES2384998T3 (en) |
IL (1) | IL175979A (en) |
MX (1) | MXPA06005112A (en) |
WO (1) | WO2004098408A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1695661B1 (en) * | 2003-11-28 | 2012-04-18 | Lazaro Eusebio Hernandez Perez | Nuclear magnetic resonance device |
US20070063801A1 (en) * | 2005-09-16 | 2007-03-22 | Laskaris Evangelos T | System and method for magnetic resonance imaging |
US8954131B2 (en) * | 2007-06-19 | 2015-02-10 | The Trustees Of Dartmouth College | Magnetic particle imaging (MPI) system and method for use of iron-based nanoparticles in imaging and diagnosis |
US8094909B2 (en) * | 2007-10-09 | 2012-01-10 | Siemens Aktiengesellschaft | Apparatus and method for remotely controlling in real time measurement parameters of a magnetic resonance (MR) scanner |
CN101498770B (en) * | 2008-01-29 | 2012-06-27 | 西门子(中国)有限公司 | Method and apparatus for cooling magnetic resonance imaging system |
ES2367066B1 (en) * | 2008-09-25 | 2012-09-13 | Ernesto Miguel González Armas | CHAMBER OF ELECTROINMUNIZATION. |
GB2483890A (en) * | 2010-09-22 | 2012-03-28 | Tesla Engineering Ltd | MRIS gradient coil assembly with screening layers connected to respective coil layers |
DE102011085171B3 (en) * | 2011-10-25 | 2013-03-28 | Siemens Aktiengesellschaft | Control device with differential control in a magnetically coupling coil system for a current-controlled, the field coils of a magnetic resonance tomograph supplying amplifier |
KR101458978B1 (en) * | 2013-10-17 | 2014-11-07 | 한국기초과학지원연구원 | Cryo probe for nuclear magnetic resonance apparatus of using closed-gas loop |
CN105425179A (en) * | 2015-12-25 | 2016-03-23 | 苏州露宇电子科技有限公司 | Remote control type nuclear magnetic resonance analyzer |
CN109199326A (en) * | 2017-07-07 | 2019-01-15 | 聚和医疗器械(杭州)有限公司 | Chinese medicine electromagnetic signal diagnosis and therapy system |
CN107390149B (en) * | 2017-07-21 | 2019-12-13 | 上海联影医疗科技有限公司 | gradient coil polarity detection method, storage medium and magnetic resonance scanning system |
SG11202011371QA (en) * | 2018-05-15 | 2020-12-30 | Holobeam Tech Inc | Precision delivery of energy utilizing holographic energy teleportation (het) with time-correlated standing-wave interference and coherent intensity amplification |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6113143A (en) * | 1984-06-29 | 1986-01-21 | Hitachi Ltd | Inspection apparatus using nuclear magnetic resonance |
AU7223391A (en) * | 1989-11-22 | 1991-06-13 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Apparatus for hyperthermia treatment of cancer |
CN1077655A (en) * | 1992-11-21 | 1993-10-27 | 邹剑钢 | Medical biologic NMR technique |
JP3501414B2 (en) * | 1994-03-17 | 2004-03-02 | 東芝医用システムエンジニアリング株式会社 | Magnetic resonance diagnostic equipment |
CN1109731A (en) * | 1994-08-29 | 1995-10-11 | 李宗诚 | Biological nucleonic resonant spectrum therapy apparatus |
US5690109A (en) * | 1995-06-23 | 1997-11-25 | Govind; Rakesh | Method of destructive, noninvasive hyperpyrexia of tissues and organisms utilizing nuclear magnetic resonance |
DE19707451A1 (en) | 1997-02-25 | 1998-08-27 | Werner Alois Prof Dipl Kaiser | Arrangement for magnetic resonance examination and hyperthermia treatment |
US5919135A (en) * | 1997-02-28 | 1999-07-06 | Lemelson; Jerome | System and method for treating cellular disorders in a living being |
US7048716B1 (en) * | 1997-05-15 | 2006-05-23 | Stanford University | MR-compatible devices |
WO1998052465A1 (en) * | 1997-05-23 | 1998-11-26 | Transurgical, Inc. | Mri-guided therapeutic unit and methods |
AU1261299A (en) * | 1997-11-28 | 1999-06-16 | Masayuki Matsuura | Method of wave therapy and apparatus therefor |
DE19932580C2 (en) | 1998-11-30 | 2003-07-03 | Forsch Innovative Medizinische | Hyperthermia device |
US6501979B1 (en) * | 2000-03-09 | 2002-12-31 | Koninklijke Philips Electronics N.V. | Methods and devices for combined ECG and PPU controlled magnetic resonance imaging |
CN1283209C (en) * | 2001-06-26 | 2006-11-08 | 西门子公司 | Magnetic resonance system and method for operation the same |
US6584337B2 (en) * | 2001-11-21 | 2003-06-24 | General Electric Company | Method and system for extended volume imaging using MRI |
JP2003245365A (en) * | 2002-02-22 | 2003-09-02 | Masahide Ichikawa | Destroying apparatus for aids tissue and articular rheumatism by micro-electromagnetic wave |
JP2003305019A (en) | 2002-04-15 | 2003-10-28 | Ge Medical Systems Global Technology Co Llc | Therapeutic apparatus |
EP1695661B1 (en) * | 2003-11-28 | 2012-04-18 | Lazaro Eusebio Hernandez Perez | Nuclear magnetic resonance device |
-
2003
- 2003-11-28 EP EP03772935A patent/EP1695661B1/en not_active Expired - Lifetime
- 2003-11-28 US US10/579,752 patent/US7423429B2/en not_active Expired - Fee Related
- 2003-11-28 AT AT03772935T patent/ATE553697T1/en active
- 2003-11-28 CN CN2003801107538A patent/CN1878498B/en not_active Expired - Fee Related
- 2003-11-28 ES ES03772935T patent/ES2384998T3/en not_active Expired - Lifetime
- 2003-11-28 AU AU2003279601A patent/AU2003279601A1/en not_active Abandoned
- 2003-11-28 WO PCT/MX2003/000105 patent/WO2004098408A1/en active Application Filing
- 2003-11-28 KR KR1020067012214A patent/KR100929545B1/en active IP Right Grant
- 2003-11-28 JP JP2004571598A patent/JP2007528231A/en active Pending
- 2003-11-28 CA CA2587828A patent/CA2587828C/en not_active Expired - Fee Related
-
2006
- 2006-05-08 MX MXPA06005112A patent/MXPA06005112A/en active IP Right Grant
- 2006-05-28 IL IL175979A patent/IL175979A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
WO2004098408A1 (en) | 2004-11-18 |
US7423429B2 (en) | 2008-09-09 |
KR20060123357A (en) | 2006-12-01 |
IL175979A0 (en) | 2006-10-05 |
ATE553697T1 (en) | 2012-05-15 |
US20070080688A1 (en) | 2007-04-12 |
ES2384998T3 (en) | 2012-07-16 |
AU2003279601A1 (en) | 2004-11-26 |
KR100929545B1 (en) | 2009-12-03 |
MXPA06005112A (en) | 2007-01-26 |
EP1695661A1 (en) | 2006-08-30 |
CN1878498B (en) | 2013-03-06 |
JP2007528231A (en) | 2007-10-11 |
CA2587828A1 (en) | 2004-11-18 |
CN1878498A (en) | 2006-12-13 |
CA2587828C (en) | 2016-08-23 |
IL175979A (en) | 2011-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL175979A (en) | Nuclear magnetic resonance device | |
Ladd et al. | Pros and cons of ultra-high-field MRI/MRS for human application | |
Hensley et al. | Combining magnetic particle imaging and magnetic fluid hyperthermia in a theranostic platform | |
Hijnen et al. | Thermal combination therapies for local drug delivery by magnetic resonance-guided high-intensity focused ultrasound | |
EP2877089B1 (en) | Radiotherapy system integrating a radiation source with a magnetic resonance imaging apparatus with movable magnet components | |
Ozenne et al. | MRI monitoring of temperature and displacement for transcranial focus ultrasound applications | |
Liney et al. | experimental results from a prototype high‐field inline MRI‐linac | |
Steyn et al. | Nuclear magnetic resonance imaging of the prostate | |
US20150208994A1 (en) | Ct/mri integrated system for the diagnosis of acute strokes and methods thereof | |
Cho et al. | Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel 1 H-magnetic resonance spectroscopy and 18 F-fluorodeoxyglucose positron emission tomography | |
Chaplin et al. | Multi-focal HIFU reduces cavitation in mild-hyperthermia | |
Leung et al. | Comparison between MR and CT imaging used to correct for skull-induced phase aberrations during transcranial focused ultrasound | |
Lee et al. | Predicting response to radiotherapy of intracranial metastases with hyperpolarized^ 13 13 C MRI | |
van Houtum et al. | Feasibility of 31P spectroscopic imaging at 7 T in lung carcinoma patients | |
Iftimia et al. | Advances in Optical Imaging for Clinical Medicine | |
Hu et al. | Diffusion-weighted MR imaging to evaluate immediate response to irreversible electroporation in a rabbit VX2 liver tumor model | |
Whelan et al. | MRI Linac systems | |
Deng et al. | Improved vessel–tissue contrast and image quality in 3D radial sampling‐based 4D‐MRI | |
Jordan | State of the art in magnetic resonance imaging | |
Laakso et al. | Docetaxel chemotherapy response in PC3 prostate cancer mouse model detected by rotating frame relaxations and water diffusion | |
Breto et al. | Analysis of magnetic resonance image signal fluctuations acquired during MR-guided radiotherapy | |
Gach et al. | Cervical Cancer Tumor Delineation for Brachytherapy Using Diffusion Weighted Images | |
Leung | Leveraging Simulations to Improve Focused Ultrasound Brain Treatments | |
de Waard-Schalkx et al. | Recent developments in medical techniques involving ionising or non-ionising radiation: update 2014 | |
Bourland et al. | The evolving role of biological imaging in stereotactic radiosurgery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060615 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20091125 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 553697 Country of ref document: AT Kind code of ref document: T Effective date: 20120515 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 60340668 Country of ref document: DE Effective date: 20120614 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2384998 Country of ref document: ES Kind code of ref document: T3 Effective date: 20120716 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 553697 Country of ref document: AT Kind code of ref document: T Effective date: 20120418 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120418 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120418 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120418 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120719 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120820 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120418 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120418 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120418 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120418 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120418 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120418 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120418 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120418 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120418 |
|
26N | No opposition filed |
Effective date: 20130121 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 60340668 Country of ref document: DE Effective date: 20130121 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120718 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121130 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121130 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121128 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121130 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120418 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121128 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031128 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20181129 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20181218 Year of fee payment: 16 Ref country code: FR Payment date: 20181130 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20181224 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20181201 Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60340668 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20191201 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20191128 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191201 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191128 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191130 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200603 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20210528 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191129 |